Compare RGS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGS | TIL |
|---|---|---|
| Founded | 1922 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 74.7M |
| IPO Year | 1994 | 2021 |
| Metric | RGS | TIL |
|---|---|---|
| Price | $23.13 | $8.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 8.9K | ★ 61.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.24 | ★ 52.54 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $210,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.13 | ★ N/A |
| Revenue Growth | ★ 3.52 | N/A |
| 52 Week Low | $15.00 | $5.67 |
| 52 Week High | $31.50 | $42.75 |
| Indicator | RGS | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 56.40 |
| Support Level | $18.63 | $6.85 |
| Resistance Level | $23.65 | $9.81 |
| Average True Range (ATR) | 0.68 | 0.58 |
| MACD | 0.21 | 0.16 |
| Stochastic Oscillator | 70.73 | 60.26 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.